Key result
High-dose Nifekalant (10-times clinical dose) induced torsades de pointes in 100% of atrioventricular block dogs, whereas the clinical dose did not induce the arrhythmia.
Why the study?
What are the electropharmacological and proarrhythmic effects of Nifekalant in canine models?
What are the electropharmacological and proarrhythmic effects of Nifekalant in canine models?
Absolute Event Rate: 100% vs 0%
Nifekalant appears safe at clinical doses, but high doses can cause QT prolongation and torsades de pointes, particularly in the setting of bradycardia.
No takes yet. Share an insight, caveat, or question.
Nifekalant shows dose-dependent effects in canine models; leaves open human proarrhythmic risk assessment.
Satoh et al. (2004) studied Animal model (dogs) (n=16). Nifekalant Hydrochloride vs. Clinical/low dose was evaluated on Torsades de pointes. High-dose Nifekalant (10-times clinical dose) induced torsades de pointes in 100% of atrioventricular block dogs, whereas the clinical dose did not induce the arrhythmia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: